Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 22-Jun-22 4:55 PM View:  | Poirier Michael S. Chairman and CEO Director | Ritter Pharmaceuticals, Inc. (QLGN) | 22-Jun-22 | Private Purchase | 30,000 | $0.57 | $17,100.00 | 17% 180.21K to 210.21K | |
| 15-Jun-22 4:05 PM View: | Broidrick Amy S. President/CSO Director | Ritter Pharmaceuticals, Inc. (QLGN) | 14-Jun-22 | Private Purchase | 30,000 | $0.62 | $18,600.00 | 667% 4.5K to 34.5K | |
| 20-Aug-21 3:05 PM View: | Kruger Kurt H Director | Ritter Pharmaceuticals, Inc. (QLGN) | 19-Aug-21 | Market Purchase | 8,000 | $1.23 | $9,800.00 | 80% 10.0K to 18.0K | 1% |
| 26-Apr-21 6:16 PM View: | Broidrick Amy S. EVP, Chief Strategy Officer Director | Ritter Pharmaceuticals, Inc. (QLGN) | 26-Apr-21 | Market Purchase | 4,500 | $2.03 | $9,135.00 | 100% 0 to 4.5K | (< 1%) |
| 21-Apr-21 3:18 PM View: | Poirier Michael S. Chairman, CEO & President Director | Ritter Pharmaceuticals, Inc. (QLGN) | 20-Apr-21 | Market Purchase | 11,005 | $1.80 | $19,809.00 | 7% 169.2K to 180.21K | < 1% |
| 19-Apr-21 6:15 AM View: | Lotz Christopher L. Vice President of Finance, CFO | Ritter Pharmaceuticals, Inc. (QLGN) | 16-Apr-21 | Market Purchase | 2,700 | $1.86 | $5,022.00 | 27% 9.84K to 12.54K | (2%) |
| 30-Dec-20 6:05 AM View: | Kruger Kurt H Director | Ritter Pharmaceuticals, Inc. (QLGN) | 29-Dec-20 | Market Purchase | 4,000 | $2.93 | $11,740.00 | 67% 6.0K to 10.0K | 3% |
| 23-Nov-20 9:11 PM View: | Kruger Kurt H Director | Ritter Pharmaceuticals, Inc. (QLGN) | 23-Nov-20 | Market Purchase | 4,600 | $3.46 | $15,925.20 | 329% 1.4K to 6.0K | (7%) |
| 23-Nov-20 9:11 PM View: | Kruger Kurt H Director | Ritter Pharmaceuticals, Inc. (QLGN) | 20-Nov-20 | Market Purchase | 1,400 | $3.55 | $4,968.60 | 100% 0 to 1.4K | (10%) |
| 27-May-20 6:04 PM View: | Poirier Michael S. Chairman, President and CEO Director | Ritter Pharmaceuticals, Inc. (QLGN) | 22-May-20 | Acquisition (other) | 169,192 | -- | -- | 100% 0 to 169.19K | |
| 27-May-20 6:03 PM View: | Lotz Christopher L. Vice President of Finance, CFO | Ritter Pharmaceuticals, Inc. (QLGN) | 22-May-20 | Acquisition (other) | 9,841 | -- | -- | 100% 0 to 9.84K | |
| 23-Apr-20 4:15 PM View: | Foehr Matthew W Director | Ritter Pharmaceuticals, Inc. (QLGN) | 10-Apr-20 | Grant | 38,461 | -- | -- | 38% 100.17K to 138.63K | |
| 16-Mar-20 5:53 PM View: | Doyle Noah Director | Ritter Pharmaceuticals, Inc. (QLGN) | 12-Mar-20 | Market Sale | 500,000 | $0.22 | $110,000.00 | (40%) 1.24M to 739.33K | 45% |
| 13-Mar-20 6:13 PM View: | Ritter Andrew J CEO and President Director | Ritter Pharmaceuticals, Inc. (QLGN) | 04-Mar-20 | Market Sale | 18,750 | $0.38 | $7,042.50 | (19%) 101.1K to 82.35K | 67% |
| 13-Mar-20 6:26 PM View: | Ritter Ira E. COB, CSO Director | Ritter Pharmaceuticals, Inc. (QLGN) | 04-Mar-20 | Market Sale Duplicate | 18,750 | $0.38 | $7,042.50 | (19%) 101.1K to 82.35K | 67% |
| 27-Feb-20 9:00 PM View: | Doyle Noah Director | Ritter Pharmaceuticals, Inc. (QLGN) | 25-Feb-20 | Option Exercise | 500,000 | $0.15 | $75,000.00 | 68% 739.33K to 1.24M | |
| 23-Apr-20 4:15 PM View: | Foehr Matthew W Director | Ritter Pharmaceuticals, Inc. (QLGN) | 21-Jan-20 | Conversion | 76,923 | -- | -- | 331% 23.25K to 100.17K | |
| 20-Aug-18 5:19 PM View: | Foehr Matthew W Director | Ritter Pharmaceuticals, Inc. (QLGN) | 17-Aug-18 | Market Purchase | 19,751 | $2.04 | $40,292.00 | 56% 35.0K to 54.75K | (94%) |
| 27-Oct-17 1:49 PM View: | Javelin Venture Partners, L... 10% Owner | Ritter Pharmaceuticals, Inc. (QLGN) | 03-Oct-17 | Purchase | 5,000,000 | -- | -- | 244% 2.05M to 7.05M | |
| 27-Oct-17 2:00 PM View: | Ritter Andrew J President 10% Owner | Ritter Pharmaceuticals, Inc. (QLGN) | 03-Oct-17 | Purchase Duplicate | 187,500 | -- | -- | 23% 823.52K to 1.01M | |
| 27-Oct-17 1:53 PM View: | Doyle Noah Director 10% Owner | Ritter Pharmaceuticals, Inc. (QLGN) | 03-Oct-17 | Purchase Duplicate | 5,000,000 | -- | -- | 209% 2.39M to 7.39M | |
| 27-Oct-17 1:57 PM View: | Ritter Ira E. Exec. Chairman, CSO Director 10% Owner | Ritter Pharmaceuticals, Inc. (QLGN) | 03-Oct-17 | Purchase | 187,500 | -- | -- | 23% 823.52K to 1.01M | |
| 18-May-17 3:39 PM View: | Foehr Matthew W Director | Ritter Pharmaceuticals, Inc. (QLGN) | 18-May-17 | Market Purchase | 18,000 | $0.62 | $11,154.60 | 106% 17.0K to 35.0K | (98%) |
| 12-May-17 4:38 PM View: | Step Michael D CEO Director | Ritter Pharmaceuticals, Inc. (QLGN) | 11-May-17 | Market Purchase | 13,000 | $0.62 | $8,006.70 | 35% 37.0K to 50.0K | (98%) |
| 28-Feb-17 10:00 PM View: | Step Michael D CEO Director | Ritter Pharmaceuticals, Inc. (QLGN) | 27-Feb-17 | Market Purchase | 10,000 | $2.65 | $26,480.00 | 37% 27.0K to 37.0K | (100%) |
| 24-Feb-16 6:28 PM View: | Ritter Andrew J President Director 10% Owner | Ritter Pharmaceuticals, Inc. (QLGN) | 22-Feb-16 | Market Purchase | 6,250 | $1.60 | $10,000.00 | < 1% 817.27K to 823.52K | (99%) |
| 24-Feb-16 6:32 PM View: | Ritter Ira E. Exec. Chairman, CSO Director 10% Owner | Ritter Pharmaceuticals, Inc. (QLGN) | 22-Feb-16 | Market Purchase Duplicate | 6,250 | $1.60 | $10,000.00 | < 1% 817.27K to 823.52K | (99%) |
| 11-Jan-16 4:40 PM View: | Foehr Matthew W Director | Ritter Pharmaceuticals, Inc. (QLGN) | 08-Jan-16 | Market Purchase | 13,000 | $1.64 | $21,320.00 | 325% 4.0K to 17.0K | (99%) |
| 08-Jan-16 6:15 PM View: | Step Michael D CEO Director | Ritter Pharmaceuticals, Inc. (QLGN) | 07-Jan-16 | Market Purchase | 27,000 | $1.48 | $39,960.00 | 100% 0 to 27.0K | (99%) |
| 30-Jun-15 8:09 PM View: | Ritter Ira E. Exec. Chairman, CSO Director | Ritter Pharmaceuticals, Inc. (QLGN) | 29-Jun-15 | Conversion Duplicate | 817,272 | -- | -- | 100% 0 to 817.27K | |
| 30-Jun-15 8:05 PM View: | Javelin Venture Partners I ... 10% Owner | Ritter Pharmaceuticals, Inc. (QLGN) | 29-Jun-15 | Conversion | 322,753 | -- | -- | 100% 0 to 322.75K | |
| 30-Jun-15 8:11 PM View: | Stonehenge Partners LLC 10% Owner | Ritter Pharmaceuticals, Inc. (QLGN) | 29-Jun-15 | Conversion | 817,272 | -- | -- | 100% 0 to 817.27K | |
| 30-Jun-15 8:02 PM View: | Doyle Noah Director | Ritter Pharmaceuticals, Inc. (QLGN) | 29-Jun-15 | Conversion | 1,570,560 | -- | -- | 196% 800.0K to 2.37M | |
| 30-Jun-15 8:08 PM View: | Ritter Andrew J President Director | Ritter Pharmaceuticals, Inc. (QLGN) | 29-Jun-15 | Conversion Duplicate | 817,272 | -- | -- | 100% 0 to 817.27K | |
| 30-Jun-15 8:03 PM View: | Javelin Venture Partners, L... 10% Owner | Ritter Pharmaceuticals, Inc. (QLGN) | 29-Jun-15 | Conversion | 1,247,800 | -- | -- | 156% 800.0K to 2.05M | |
| 25-Jun-15 8:56 PM View: | Foehr Matthew W Director | Ritter Pharmaceuticals, Inc. (QLGN) | 24-Jun-15 | Market Purchase | 4,000 | $5.00 | $20,000.00 | 100% 0 to 4.0K | (100%) |
| 25-Jun-15 9:04 PM View: | Javelin Venture Partners, L... 10% Owner | Ritter Pharmaceuticals, Inc. (QLGN) | 24-Jun-15 | Market Purchase | 800,000 | $5.00 | $4,000,000.00 | 100% 0 to 800.0K | (100%) |
| 25-Jun-15 8:58 PM View: | Proehl Gerald T Director | Ritter Pharmaceuticals, Inc. (QLGN) | 24-Jun-15 | Market Purchase | 50,000 | $5.00 | $250,000.00 | 100% 0 to 50.0K | (100%) |
| 25-Jun-15 9:03 PM View: | Doyle Noah Director | Ritter Pharmaceuticals, Inc. (QLGN) | 24-Jun-15 | Market Purchase Duplicate | 800,000 | $5.00 | $4,000,000.00 | 100% 0 to 800.0K | (100%) |
